<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Disorders associated with multiple lentigines</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Disorders associated with multiple lentigines</h1>
<div class="graphic"><div class="figure"><div class="ttl">Disorders associated with multiple lentigines</div><div class="cntnt"><table cellspacing="0"><colgroup span="4" width="25%"></colgroup> <tbody> <tr> <td class="subtitle1">Disorder</td> <td class="subtitle1">Genetics</td> <td class="subtitle1">Features of lentigines</td> <td class="subtitle1">Other manifestations</td> </tr> <tr> <td class="subtitle2_left" colspan="4">Generalized</td> </tr> <tr> <td class="indent1">Noonan syndrome with multiple lentigines (LEOPARD syndrome)</td> <td> <ul> <li>AD</li> <li><em>PTPN11</em> (nonreceptor protein tyrosine phosphatase) <em>RAF1</em></li> </ul> </td> <td> <ul> <li>Onset in infancy/early childhood</li> <li>Generalized</li> <li>Spare oral mucosa</li> <li>Also café-noir and café-au-lait macules</li> </ul> </td> <td> <ul> <li>Electrocardiogram changes</li> <li>Ocular hypertelorism</li> <li>Pulmonary stenosis, hypertrophic obstructive cardiomyopathy</li> <li>Abnormal genitalia</li> <li>Retardation of growth and intellectual disability</li> <li>Deafness</li> <li>Also triangular facies, skeletal abnormalities</li> </ul> </td> </tr> <tr> <td class="indent1">Carney complex (NAME/LAMB syndrome)</td> <td> <ul> <li>AD</li> <li><em>PRKAR1A</em> (type 1-alpha regulatory subunit of protein kinase A)</li> </ul> </td> <td> <ul> <li>Onset in early childhood, but the full distribution is not seen until puberty</li> <li>Generalized</li> <li>May involve eyelids, conjunctiva, vermilion border of lips, genitals</li> <li>Usually spare oral mucosa</li> </ul> </td> <td> <ul> <li>Atrial myxomas</li> <li>Mucocutaneous myxomas (often on eyelids, ears, nipples)</li> <li>Blue nevi (epithelioid variant)</li> <li>Pigmented nodular adrenocortical disease</li> <li>Pituitary, thyroid, and testicular (calcifying Sertoli cell) tumors</li> <li>Myxoid mammary fibroadenomas</li> <li>Psammomatous melanotic schwannomas</li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1">Arterial dissection</td> <td> <ul> <li>AD versus AR</li> </ul> </td> <td> <ul> <li>Onset in childhood</li> <li>Generalized</li> </ul> </td> <td> <ul> <li>Dissection of aortic, internal carotid, and vertebral arteries</li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="4">Localized</td> </tr> <tr> <td class="indent1">Peutz-Jeghers syndrome</td> <td> <ul> <li>AD</li> <li><em>STK11</em> (serine/threonine protein kinase 11)</li> </ul> </td> <td> <ul> <li>Onset in infancy/early childhood</li> <li>Perioral (may fade), oral mucosa (persist), hands, feet</li> <li>Longitudinal melanonychia</li> </ul> </td> <td> <ul> <li>Multiple hamartomatous gastrointestinal polyps (intussusception may occur)</li> <li>Increased incidence of gastrointestinal, ovarian, testicular, cervical (adenoma malignum), pancreatic, and breast cancers</li> </ul> </td> </tr> <tr> <td class="indent1">Laugier-Hunziker syndrome</td> <td> <ul> <li>AD</li> <li>?</li> </ul> </td> <td> <ul> <li>As in Peutz-Jeghers</li> <li>Also genital melanosis</li> </ul> </td> <td> <ul> <li>None</li> <li>May see similar lesions in patients receiving zidovudine (AZT)</li> </ul> </td> </tr> <tr> <td class="indent1">Cowden disease</td> <td> <ul> <li>AD</li> <li><em>PTEN</em> (phosphatase and tensin homolog)</li> </ul> </td> <td> <ul> <li>Onset in childhood to young adulthood</li> <li>Periorificial and acral lentigines (occasionally seen)</li> <li>Café-au-lait macules</li> </ul> </td> <td> <ul> <li>Facial trichilemmomas</li> <li>Oral mucosal cobblestoning</li> <li>Acral keratoses</li> <li>Lipomas, sclerotic fibromas</li> <li>Macrocephaly, adenoid facies, mental retardation</li> <li>Thyroid adenomas/carcinoma</li> <li>Breast fibroadenomas/carcinoma</li> <li>Gastrointestinal hamartomas/carcinoma</li> <li>Uterine fibroids/carcinoma</li> </ul> </td> </tr> <tr> <td class="indent1">Bannayan-Riley-Ruvalcaba syndrome</td> <td> <ul> <li>AD</li> <li><em>PTEN</em> (phosphatase and tensin homolog)</li> </ul> </td> <td> <ul> <li>Genital melanosis</li> <li>Café-au-lait macules</li> </ul> </td> <td> <ul> <li>Capillary and/or venous malformations</li> <li>Lipomas</li> <li>Facial trichilemmomas</li> <li>Acanthosis nigricans</li> <li>Macrocephaly, mental retardation</li> <li>Gastrointestinal hamartomas</li> <li>Thyroid tumors</li> </ul> </td> </tr> <tr> <td class="indent1">Centrofacial lentiginosis</td> <td> <ul> <li>AD</li> <li>?</li> </ul> </td> <td> <ul> <li>Onset in infancy; increase in number in childhood</li> <li>Butterfly distribution on nose and cheeks &gt; forehead, eyelids, upper lip</li> </ul> </td> <td> <ul> <li>Neuropsychiatric disorders</li> <li>Osseous anomalies</li> </ul> </td> </tr> <tr> <td class="indent1">Inherited patterned lentiginosis</td> <td> <ul> <li>AD</li> <li>Black individuals with light brown skin</li> </ul> </td> <td> <ul> <li>Central face, lips &gt; buttocks, elbows, hands, feet</li> <li>Usually spare oral mucosa</li> </ul> </td> <td> <ul> <li>None</li> </ul> </td> </tr> <tr> <td class="indent1">Partial unilateral lentiginosis</td> <td> <ul> <li>?</li> <li>?</li> </ul> </td> <td> <ul> <li>Onset in childhood, with wavefront extension over time</li> <li>Segmental distribution (no background hyperpigmentation)</li> <li>Often have café-au-lait macules in same area</li> <li>Can have ocular lesions</li> </ul> </td> <td> <ul> <li>May be associated with segmental neurofibromatosis</li> <li>A few reports of associated mental retardation and seizures</li> </ul> </td> </tr> <tr> <td class="indent1">Xeroderma pigmentosum</td> <td> <ul> <li>AR</li> <li>XP-A through G and variant (abnormal nucleotide excision repair)</li> </ul> </td> <td> <ul> <li>Favor (but not limited to) sun-exposed sites (represent solar lentigines)</li> </ul> </td> <td> <ul> <li>Photosensitivity</li> <li>Markedly increased incidence of basal and squamous cell carcinomas and melanoma</li> <li>Also increased incidence of internal malignancies</li> <li>CNS degeneration in a subset of patients</li> </ul> </td> </tr> <tr> <td class="indent1">Neurofibromatosis type 1</td> <td> <ul> <li>AD</li> <li><em>NFI</em> (neurofibromin)</li> </ul> </td> <td> <ul> <li>"Freckling" (actually represents lentigines) favors flexural sites (neck, axillae, groin), but may be generalized</li> <li>≥6 café-au-lait macules (in 80 to 90% of patients)</li> </ul> </td> <td> <ul> <li>Cutaneous neurofibromas</li> <li>Lisch nodules (iris hamartomas)</li> <li>Optic glioma</li> <li>Distinct bone lesions (eg, sphenoid dysplasia)</li> <li>Macrocephaly</li> <li>Learning disabilities</li> </ul> </td> </tr> <tr> <td class="indent1">Legius (neurofibromatosis type 1-like) syndrome</td> <td> <ul> <li>AD</li> <li><em>SPRED1</em> (Sprouty-related EVH1 domain containing protein 1)</li> </ul> </td> <td> <ul> <li>Intertriginous "freckling" (actually lentigines) in approximately half of patients</li> <li>≥6 café-au-lait macules in &gt;80% of patients</li> </ul> </td> <td> <ul> <li><strong>Lacks</strong> neurofibromas, Lisch nodules, optic gliomas, and typical osseous lesions of neurofibromatosis type 1</li> <li>Macrocephaly and learning disabilities are common</li> <li>Occasionally lipomas, hypopigmented macules, and vascular anomalies</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_footnotes">LEOPARD: lentigines, electrocardiogram abnormalities, ocular hypertelorism, pulmonic stenosis, abnormal genitalia, retardation of growth, and sensorineural deafness; 

	AD: autosomal dominant; 

	NAME: nevi, atrial myxoma, ephelides; 

	LAMB: lentigines, atrial myxoma, blue nevi; AR: autosomal recessive; 

	CNS: central nervous system.</div><div id="graphicVersion">Graphic 66428 Version 8.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
